Aliases & Classifications for Mood Disorder

MalaCards integrated aliases for Mood Disorder:

Name: Mood Disorder 12 14
Mood Disorders 51 40 41 69
Episodic Mood Disorder 12 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3324
MeSH 41 D019964
NCIt 46 C92200

Summaries for Mood Disorder

MedlinePlus : 40 Most people feel sad or irritable from time to time. They may say they're in a bad mood. A mood disorder is different. It affects a person's everyday emotional state. Nearly one in ten people aged 18 and older have mood disorders. These include depression and bipolar disorder (also called manic depression). Mood disorders can increase a person's risk for heart disease, diabetes, and other diseases. Treatments include medication, psychotherapy, or a combination of both. With treatment, most people with mood disorders can lead productive lives.

MalaCards based summary : Mood Disorder, also known as mood disorders, is related to delusional disorder and dysthymic disorder, and has symptoms including psychiatric symptom and alexithymia. An important gene associated with Mood Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Valproic Acid and Amitriptyline have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A cognitive disorder that involves an excessive, irrational dread of everyday situations.

Wikipedia : 72 Mood disorder, also known as mood (affective) disorders, is a group of conditions where a disturbance in... more...

Related Diseases for Mood Disorder

Diseases related to Mood Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 217)
# Related Disease Score Top Affiliating Genes
1 delusional disorder 32.6 DRD2 DRD4 TH
2 dysthymic disorder 32.2 HTR2A MAOA SLC6A4
3 postpartum depression 32.1 BDNF COMT CRH HTR1A MAOA SLC6A4
4 asperger syndrome 32.1 DISC1 MAOB SLC6A4
5 acth-secreting pituitary adenoma 32.0 CRH NR3C1 POMC
6 schizoaffective disorder 32.0 BDNF COMT DISC1 DRD2 HTR2A SLC6A4
7 atypical depressive disorder 31.8 CRH MAOA MAOB SLC6A4
8 endogenous depression 31.1 BDNF CRH HTR1A HTR2A MAOA NR3C1
9 tardive dyskinesia 30.8 COMT DRD2 HTR2A
10 mental depression 30.7 BDNF COMT CRH HTR1A HTR2A MAOA
11 major depressive disorder 30.6 BDNF CACNA1C COMT CREB1 CRH DISC1
12 social phobia 30.5 DRD2 MAOA SLC6A4
13 alcohol use disorder 30.5 DRD2 SLC6A4
14 alexithymia 30.4 COMT DRD2 HTR1A SLC6A4
15 alcohol abuse 30.4 BDNF DRD2 DRD4 SLC6A4
16 bipolar disorder 30.4 BDNF CACNA1C COMT CREB1 CRH DISC1
17 bipolar i disorder 30.3 BDNF COMT HTR1A HTR2A SLC6A4
18 kleptomania 30.3 HTR1A MAOA SLC6A4
19 traumatic brain injury 30.3 BDNF COMT DRD2
20 brain injury 30.3 BDNF COMT DRD2
21 pathological gambling 30.2 DRD2 DRD4 HTR2A MAOA MAOB SLC6A4
22 temporal lobe epilepsy 30.2 BDNF HTR1A NPY
23 cocaine dependence 30.1 DRD2 POMC SLC6A4
24 paranoid schizophrenia 30.1 BDNF COMT HTR2A MAOA SLC6A4
25 anxiety 30.1 BDNF COMT CRH HTR1A HTR2A MAOA
26 eating disorder 30.1 BDNF COMT DRD2 NPY POMC SLC6A4
27 schizophreniform disorder 30.1 COMT DRD2
28 tobacco addiction 30.1 COMT DRD2 HTR2A MAOA TPH1
29 substance abuse 30.0 BDNF COMT DRD2 DRD4 HTR1B MAOA
30 substance dependence 30.0 BDNF DRD2 DRD4 HTR1B MAOA POMC
31 schizophrenia 30.0 BDNF CACNA1C COMT CREB1 DISC1 DRD2
32 generalized anxiety disorder 29.8 BDNF DRD2 HTR1A HTR2A MAOA SLC6A4
33 borderline personality disorder 29.8 BDNF COMT HTR1A HTR1B HTR2A MAOA
34 narcolepsy 29.7 COMT DRD2 HTR2A SLC18A2 TPH1
35 personality disorder 29.6 BDNF COMT DRD2 DRD4 HTR1A HTR1B
36 obsessive-compulsive disorder 29.6 BDNF COMT DRD2 DRD4 HTR1A HTR1B
37 panic disorder 29.6 BDNF COMT CRH HTR1A HTR2A MAOA
38 body mass index quantitative trait locus 11 29.6 CRH DRD2 NPY NR3C1 POMC
39 post-traumatic stress disorder 29.4 BDNF COMT CRH DRD2 HTR2A MAOA
40 migraine with or without aura 1 29.4 COMT DRD2 DRD4 HTR1A HTR1B HTR2A
41 autism 29.2 BDNF CACNA1C COMT DISC1 DRD2 DRD4
42 autism spectrum disorder 29.2 BDNF CACNA1C COMT DISC1 DRD2 DRD4
43 psychotic disorder 28.7 BDNF COMT DISC1 DRD2 DRD4 HTR1A
44 attention deficit-hyperactivity disorder 28.6 BDNF COMT DRD2 DRD4 HTR1A HTR1B
45 alcohol dependence 28.3 BDNF COMT DRD2 DRD4 HTR1A HTR1B
46 organic mood syndrome 11.0
47 panic disorder 1 10.7
48 schizophrenia 4 10.7
49 schizophrenia 2 10.7
50 schizophrenia 9 10.7

Comorbidity relations with Mood Disorder via Phenotypic Disease Network (PDN): (show all 11)


Acute Cystitis Anxiety
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Mood Disorder:



Diseases related to Mood Disorder

Symptoms & Phenotypes for Mood Disorder

UMLS symptoms related to Mood Disorder:


psychiatric symptom, alexithymia

MGI Mouse Phenotypes related to Mood Disorder:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.51 CRH CACNA1C DISC1 COMT DRD2 CREB1
2 homeostasis/metabolism MP:0005376 10.36 BDNF CRH CACNA1C DISC1 COMT DRD2
3 cardiovascular system MP:0005385 10.31 CACNA1C COMT DRD2 CREB1 HTR1A NR3C1
4 cellular MP:0005384 10.26 CREB1 BDNF CRH CACNA1C DRD2 MAOB
5 growth/size/body region MP:0005378 10.25 BDNF CRH DISC1 DRD2 CREB1 NPY
6 endocrine/exocrine gland MP:0005379 10.23 BDNF CRH CACNA1C COMT DRD2 CREB1
7 nervous system MP:0003631 10.19 CRH CACNA1C DISC1 COMT DRD2 CREB1
8 adipose tissue MP:0005375 10.07 CRH DRD2 NPY HTR1B NR3C1 POMC
9 integument MP:0010771 10.02 BDNF CRH CACNA1C NR3C1 DRD2 TH
10 muscle MP:0005369 9.97 CACNA1C DRD2 CREB1 NR3C1 HTR1B HTR2A
11 no phenotypic analysis MP:0003012 9.76 BDNF CRH HTR1A NR3C1 HTR1B DRD2
12 renal/urinary system MP:0005367 9.5 CRH COMT MAOB DRD2 NPY NR3C1
13 respiratory system MP:0005388 9.23 CREB1 BDNF CRH COMT NR3C1 DRD2

Drugs & Therapeutics for Mood Disorder

Drugs for Mood Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 710)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 99-66-1 3121
2
Amitriptyline Approved Phase 4,Phase 3,Phase 2 50-48-6 2160
3
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59729-33-8 2771
4
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
5
Nortriptyline Approved Phase 4,Phase 1,Phase 2 72-69-5 4543
6
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
7
Perphenazine Approved Phase 4,Phase 3,Phase 2,Phase 1 58-39-9 4748
8
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 79617-96-2 68617
9
Trimipramine Approved Phase 4 739-71-9 5584 4055
10
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1 34911-55-2, 34841-39-9 444
11
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
12
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 6740-88-1 3821
13
Sevoflurane Approved, Vet_approved Phase 4,Phase 3 28523-86-6 5206
14
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54910-89-3 3386
15
Acetylcholine Approved Phase 4,Phase 2,Phase 1 51-84-3 187
16
Methyltestosterone Approved Phase 4,Phase 3 58-18-4 6010
17
Testosterone Approved, Investigational Phase 4,Phase 3 58-22-0 6013
18
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-45-6, 75614-87-8 774
19
Mianserin Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 24219-97-4 4184
20
Mirtazapine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 85650-52-8, 61337-67-5 4205
21
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-23-7 657311 5754
22
Fluvoxamine Approved, Investigational Phase 4,Phase 2 54739-18-3 5324346 3404
23
Trazodone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 19794-93-5 5533
24
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
25
Tranylcypromine Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 155-09-9 441233
26
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
27
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
28
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
29
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
30
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
31
Copper Approved, Investigational Phase 4 7440-50-8 27099
32
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757
33
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1 57-63-6 5991
34
Norethindrone Approved Phase 4 68-22-4 6230
35
Diphenhydramine Approved, Investigational Phase 4,Phase 1 58-73-1, 147-24-0 3100
36
Promethazine Approved, Investigational Phase 4,Phase 1 60-87-7 4927
37
Suvorexant Approved, Investigational Phase 4 1030377-33-3
38
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
39
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
40
Eszopiclone Approved, Investigational Phase 4,Phase 3 138729-47-2 969472
41
Reboxetine Approved, Investigational Phase 4,Phase 2,Phase 1 71620-89-8, 98769-81-4 65856 123628
42
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 132539-06-1 4585
43
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 106266-06-2 5073
44
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 298-46-4 2554
45
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10118-90-8 5281021
46
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 20748-11-2, 113-45-1 4158
47
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
48
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1 54-11-5 89594 942
49
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59467-70-8 4192
50
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19982-08-2 4054

Interventional clinical trials:

(show top 50) (show all 3818)

# Name Status NCT ID Phase Drugs
1 Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD) Unknown status NCT01272531 Phase 4 Mood stabilizer treatment
2 Efficacy of MBI for Depressive Symptoms in Patients With MS Unknown status NCT02611401 Phase 4
3 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4 Paroxetine;Sertraline;Citalopram;Venlafaxine;Amitriptyline;Escitalopram;Amitriptylinoxide;Nortriptyline;Trimipramine
4 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
5 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
6 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
7 Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
8 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
9 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
10 Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
11 Lexapro®'s Efficacy After Dose Escalation in Remission Study Unknown status NCT01594866 Phase 4 escitalopram;escitalopram
12 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
13 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
14 Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
15 Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression Unknown status NCT02042573 Phase 4 SSRI (SEROPLEX ou ZOLOFT)
16 Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate
17 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4 escitalopram 10 mg;Placebo
18 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
19 Effect of Antidepressants on White Matter Structure Unknown status NCT01492621 Phase 4 Desvenlafaxine
20 Inflammatory Markers and Cognitive Function in Major Depression Unknown status NCT01391221 Phase 4 Duloxetine
21 Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression Unknown status NCT01390662 Phase 4
22 Depression Care Management for Depressed Elders in China Primary Care Unknown status NCT01287494 Phase 4 Sertraline
23 The Effect of Duloxetine on Interoceptive Awareness Unknown status NCT00337012 Phase 4
24 Lithium and Standard Therapy in Resistant Depression Unknown status NCT00927550 Phase 4 lithium;usual care
25 Duloxetine for Major Depression in Peri-/Postmenopausal Women Unknown status NCT00889369 Phase 4 Duloxetine
26 Cymbalta for Depression as a Complication of Bereavement Unknown status NCT00658931 Phase 4 Drug treatment with Cymbalta
27 Morbidity and Mortality Among Dialysis Patients After Treatment for Depression Unknown status NCT00442429 Phase 4
28 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
29 Medications for the Treatment of Dysthymic Disorder and Double Depression Unknown status NCT00234312 Phase 4 escitalopram and sertraline
30 Estrogen and Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
31 Treatment of Mild and Subthreshold Depressive Disorders Unknown status NCT00226642 Phase 4 Sertralin;Placebo
32 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
33 Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression Unknown status NCT00106197 Phase 4 Bupropion
34 Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder Unknown status NCT02129751 Phase 4 bupropion hydrobromide;Placebo
35 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN) Unknown status NCT02051413 Phase 4 Venlafaxine extended release
36 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
37 Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder Unknown status NCT01696617 Phase 4 Aripiprazole 6-week group;Aripiprazole 8-week group
38 Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4 Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
39 Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
40 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
41 Tranylcypromine Treatment of Bipolar Depression Unknown status NCT01430455 Phase 4 Tranylcypromine
42 Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
43 Neurophysiologic Changes in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
44 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
45 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
46 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
47 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)
48 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
49 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
50 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion

Search NIH Clinical Center for Mood Disorder

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: mood disorders

Genetic Tests for Mood Disorder

Anatomical Context for Mood Disorder

MalaCards organs/tissues related to Mood Disorder:

38
Brain, Heart, Testes, Cortex, Pituitary, Thyroid, Bone

Publications for Mood Disorder

Articles related to Mood Disorder:

(show top 50) (show all 813)
# Title Authors Year
1
Risk profiles of personality traits for suicidality among mood disorder patients and community controls. ( 29141103 )
2018
2
Symptom Profile of Psychiatric Patients With Psychosis or Psychotic Mood Disorder in Prison. ( 29426253 )
2018
3
The association between low level of high-density lipoprotein cholesterol and mood disorder using time-dependent analysis. ( 28843914 )
2018
4
Independent associations and effect modification between lifetime substance use and recent mood disorder diagnosis with household food insecurity. ( 29360862 )
2018
5
Features of borderline personality disorder as a mediator of the relation between childhood traumatic experiences and psychosis-like experiences in patients with mood disorder. ( 29353179 )
2018
6
Environmental perturbation of the circadian clock during pregnancy leads to transgenerational mood disorder-like behaviors in mice. ( 28974783 )
2017
7
Mood disorder, anxiety, and suicide risk among subjects with alcohol abuse and/or dependence: a population-based study. ( 28658442 )
2017
8
Exploratory Study of the Clinical Characteristics of Adolescent Girls with a History of Physical or Sexual Abuse Consulting in a Mood Disorder Clinic. ( 28747935 )
2017
9
Prevalence and predictors of post-stroke mood disorders: A meta-analysis and meta-regression of depression, anxiety and adjustment disorder. ( 28807138 )
2017
10
Narcissistic Personality Disorder and suicidal behavior in mood disorders. ( 27816770 )
2017
11
Defective compensation over early dysneurogenesis in schizophrenia and mood disorder. ( 28666634 )
2017
12
Effect of Hypoxic Injury in Mood Disorder. ( 28717522 )
2017
13
Critical exploration of co-occurring Attention-Deficit/Hyperactivity Disorder, mood disorder and Substance Use Disorder. ( 28686107 )
2017
14
Emotion-related impulsivity and rumination predict the perimenstrual severity and trajectory of symptoms in women with a menstrually related mood disorder. ( 28898408 )
2017
15
Defining melancholia: A core mood disorder. ( 28599349 )
2017
16
The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions. ( 28681620 )
2017
17
Facilitators and Barriers to Disclosure of Postpartum Mood Disorder Symptoms to a Healthcare Provider. ( 28766092 )
2017
18
The interaction of GSK3B and FXR1 genotypes may influence the mania and depression dimensions in mood disorders. ( 28242499 )
2017
19
Is the association between offspring intelligence and parents' educational attainment influenced by schizophrenia or mood disorder in parents? ( 28868239 )
2017
20
Prolonged delirium misdiagnosed as a mood disorder. ( 29213513 )
2017
21
Genealogy Study of Three Generations of Patients with Bipolar Mood Disorder Type I. ( 28852243 )
2017
22
Comparing the Profile of Temperament and Character Dimensions in Patients with Major Depressive Disorder and Bipolar Mood Disorder with a Control Group. ( 29062365 )
2017
23
Clinical stabilisation with lacosamide of mood disorder comorbid with PTSD and fronto-temporal epilepsy. ( 28845834 )
2017
24
Chronobiological theories of mood disorder. ( 28894915 )
2017
25
Effectiveness evaluation of mood disorder treatment algorithms in Brazilian public healthcare patients. ( 28832750 )
2017
26
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. ( 28839340 )
2017
27
Creativity and Mood Disorder: A Systematic Review and Meta-Analysis. ( 28934560 )
2017
28
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. ( 28839341 )
2017
29
Factors Associated with Mood Disorder Diagnosis Among a Population Based Cohort of Men and Women Living With and Without HIV in British Columbia Between 1998 and 2012. ( 28612214 )
2017
30
Mood Disorder as an Early Presentation of Epidermoid of Quadrigeminal Cistern. ( 28694630 )
2017
31
Heterozygosity for the Mood Disorder-Associated Variant Gln460Arg Alters P2X7 Receptor Function and Sleep Quality. ( 29079688 )
2017
32
Analyzing the Effect of V66M Mutation in BDNF in Causing Mood Disorders: A Computational Approach. ( 28427565 )
2017
33
Hypersomnolence, Hypersomnia, and Mood Disorders. ( 28243864 )
2017
34
The impact of schizophrenia and mood disorder risk alleles on emotional problems: investigating change from childhood to middle age. ( 29239291 )
2017
35
Could EPO studies improve mood disorder treatment strategies? ( 27967254 )
2017
36
Branched-Chain Amino Acids as New Biomarkers of Major Depression - A Novel Neurobiology of Mood Disorder. ( 27490818 )
2016
37
Anxiety or agitation in mood disorder with mixed features: A review with a focus on validity as a dimensional criterion. ( 27490837 )
2016
38
Low birth weight and features of neuroticism and mood disorder in 83a88545 participants of the UK Biobank cohort. ( 27703752 )
2016
39
Mood disorders in healthy elderly with obstructive sleep apnea: a gender effect. ( 27198948 )
2016
40
Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression ("RAD") project. ( 26980207 )
2016
41
Preliminary assessment of pre-morbid DNA methylation in individuals at high genetic risk of mood disorders. ( 27440233 )
2016
42
Treatment of Postpartum Mood Disorder in Iran. ( 27903108 )
2016
43
Changes in cortical N-methyl-D-aspartate receptors and post-synaptic density protein 95 in schizophrenia, mood disorders and suicide. ( 26013316 )
2016
44
A comparative meta-analysis of TEMPS scores across mood disorder patients, their first-degree relatives, healthy controls, and other psychiatric disorders. ( 26897455 )
2016
45
The Effect of Family-Centered Psycho-Education on Mental Health and Quality of Life of Families of Adolescents with Bipolar Mood Disorder: A Randomized Controlled Clinical Trial. ( 27382589 )
2016
46
A Magnetic Resonance Spectroscopy study of lovastatin for treating Bipolar Mood disorder, A-4 week Randomized Double Blind, Placebo- Controlled Clinical Trial. ( 27804862 )
2016
47
Effect of lithium on thyroid function in adolescents with mood disorder. ( 27931904 )
2016
48
Exploring the Use of Information and Communication Technology by People With Mood Disorder: A Systematic Review and Metasynthesis. ( 27370327 )
2016
49
Integrating Early Intervention for Borderline Personality Disorder and Mood Disorders. ( 27144298 )
2016
50
Targeting Treatments to Improve Cognitive Function in Mood Disorder: Suggestions From Trials Using Erythropoietin. ( 27835716 )
2016

Variations for Mood Disorder

Expression for Mood Disorder

Search GEO for disease gene expression data for Mood Disorder.

Pathways for Mood Disorder

Pathways related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.5 CRH DRD2 DRD4 HTR1A HTR1B HTR2A
2
Show member pathways
12.97 BDNF CACNA1C CREB1 CRH DRD2 HTR2A
3
Show member pathways
12.64 CACNA1C COMT CREB1 DRD2 DRD4 MAOA
4 12.55 COMT CREB1 HTR1A NPY POMC TH
5 12.26 CACNA1C CREB1 DRD2 DRD4
7
Show member pathways
12.22 BDNF CACNA1C CREB1 DRD2 HTR1A HTR1B
8
Show member pathways
12.11 CACNA1C CREB1 DRD2 DRD4
9 12.02 BDNF CREB1 HTR1A HTR2A MAOA NR3C1
10
Show member pathways
11.95 DRD2 DRD4 HTR1A HTR1B HTR2A
11
Show member pathways
11.93 BDNF CACNA1C CREB1 DRD2 MAOA MAOB
12
Show member pathways
11.88 DRD2 DRD4 SLC18A2 TH
13 11.78 CREB1 CRH POMC
14 11.77 MAOA TH TPH1
15 11.71 CREB1 NR3C1 POMC
16
Show member pathways
11.71 COMT MAOA MAOB TH
17 11.68 BDNF SLC18A2 TH
18 11.66 CACNA1C HTR1A HTR1B HTR2A MAOA MAOB
19
Show member pathways
11.39 MAOA SLC6A4 TH
20
Show member pathways
11.14 COMT MAOA SLC6A4
21
Show member pathways
11.1 COMT MAOA TH TPH1
22 11.07 CACNA1C NPY SLC18A2
23 10.88 COMT MAOA MAOB TH
24
Show member pathways
10.86 COMT MAOA MAOB
25 10.79 BDNF CREB1
26
Show member pathways
10.74 MAOA MAOB
27 10.7 CACNA1C TH
28 10.61 HTR1A HTR1B HTR2A MAOA SLC18A2 SLC6A4
29 10.44 CRH POMC

GO Terms for Mood Disorder

Cellular components related to Mood Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.56 BDNF COMT CREB1 DISC1 MAOA MAOB
2 axon GO:0030424 9.02 COMT CREB1 DRD2 HTR2A TH

Biological processes related to Mood Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.97 CRH HTR1B HTR2A NPY SLC18A2
2 response to hypoxia GO:0001666 9.96 CREB1 DRD2 SLC6A4 TH
3 response to toxic substance GO:0009636 9.89 DRD2 MAOB SLC18A2 SLC6A4
4 locomotory behavior GO:0007626 9.88 DRD2 SLC18A2 TH
5 circadian rhythm GO:0007623 9.87 CREB1 SLC6A4 TPH1
6 positive regulation of fat cell differentiation GO:0045600 9.84 CREB1 HTR2A TPH1
7 social behavior GO:0035176 9.83 DRD4 SLC6A4 TH
8 feeding behavior GO:0007631 9.83 DRD2 HTR1B NPY
9 response to nicotine GO:0035094 9.8 CREB1 DRD2 TH
10 response to cocaine GO:0042220 9.8 CRH DRD2 HTR1B
11 memory GO:0007613